Nature Medicine shared on X:
“Evaluation of longitudinal blood samples reveals that CD19, CARTs could be detected at the least 10 years post-treatment in sufferers with lymphoma, with deeper profiling from a single affected person displaying that these CARTs have a dominant double unfavourable activated effector memory-like phenotype.”
Vera Ghali, Medical Physician Pediatrics, Allergy and Immunology, Member of the Lebanese Order of Physicians and Lebanese Pediatric Society, added on X:
“A longitudinal evaluation of blood samples demonstrated that CAR T19-cells can persist for greater than 10 years post-treatment in sufferers with B Cell Non Hodgkin Lymphoma (NHL) serving to to outline phenotypic, transcriptional, and clonal options related to exceptionally long-term persistence of those cells, which exhibit a predominant double-negative (DN) CD4-CD8-activated effector memory-like immunophenotype.”
